Corcept Therapeutics INC Form 4 insider transactions

Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 1,031 shares of common stock on August 10, 2026 for $114.52 per share.

William Guyer, Chief Development Officer of Corcept Therapeutics Inc, sold 16,300 shares of common stock on August 10, 2026.

William Guyer, Chief Development Officer of Corcept Therapeutics Inc, sold 3,700 shares of common stock on August 4, 2026 for $113.12 per share.

Sean Maduck, See Remarks of Corcept Therapeutics Inc, sold 20,305 shares of common stock on August 3, 2026 for $114.70 per share.

Joseph Douglas Lyon, See Remarks of Corcept Therapeutics Inc, sold 1,540 shares of common stock on August 3, 2026 for $114.16 per share.

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 80,000 shares of common stock on July 30, 2026.

James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on July 15, 2026.

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 40,000 shares of common stock on July 15, 2026.

Gary Charles Robb, Chief Business Officer at Corcept Therapeutics Inc., reported a transaction involving common stock on May 27, 2026.

Corcept Therapeutics Chief Development Officer William Guyer reported transactions involving company stock, including the acquisition of stock options and the sale of common stock.

Sean Maduck, President of Corcept Endocrinology, engaged in significant stock transactions, including acquisitions and sales, on July 1, 2026, under a Rule 10b5-1 plan.

Corcept Therapeutics Director James N. Wilson reported the sale of Corcept Therapeutics Inc. common stock valued at over $1 million, executed under a pre-established 10b5-1 trading plan.

Corcept Therapeutics Director David L. Mahoney reported a sale of 20,000 shares of common stock on June 17, 2026, for an aggregate price of $1,690,500.

Corcept Therapeutics Chief Financial Officer, Atabak Mokari, reported a series of stock transactions on June 15, 2026, including the acquisition of stock options and the sale of common stock.

Chief Development Officer William Guyer exercised options and sold 20,000 shares of Corcept Therapeutics common stock.

Chief Accounting & Technology Officer Joseph Douglas Lyon reported stock acquisitions and tax-related withholdings.

Chief Development Officer William Guyer acquired 1,754 shares of Corcept Therapeutics common stock through an incentive plan.

Corcept Therapeutics President Sean Maduck exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Corcept Therapeutics CFO Atabak Mokari exercised options and sold 40,000 shares of common stock under a 10b5-1 trading plan.

Chief Business Officer Gary Charles Robb reported recent acquisitions and tax-related dispositions of Corcept Therapeutics common stock.

Corcept Therapeutics CEO Joseph K. Belanoff reported transactions involving company stock, including acquisitions and a sale executed under a Rule 10b5-1 plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, sold 5,000 shares of common stock.

Corcept Therapeutics President Sean Maduck exercised 75,000 stock options and sold 75,000 shares under a 10b5-1 trading plan.

Director James N. Wilson reported a series of internal share transfers between family trusts and partnerships.

Corcept Therapeutics Director Leonard G. Baker Jr. acquired 12,500 stock options on May 21, 2026, as detailed in a Form 4 filing.

Director Gregg H. Alton of Corcept Therapeutics acquired 12,500 stock options with an exercise price of $59.69, vesting over one year.

Director James N. Wilson acquired 12,500 stock options in Corcept Therapeutics Inc. on May 21, 2026.

Corcept Therapeutics Director Daniel N. Swisher Jr. acquired 12,500 stock options on May 21, 2026, as detailed in a recent SEC Form 4 filing.

Corcept Therapeutics Director Joshua M. Murray acquired 12,500 stock options with an exercise price of $59.69, vesting over one year.

David L. Mahoney, a Director at Corcept Therapeutics, acquired stock options for 12,500 shares.